pediatric oncology

Optimizing Anti-GD2 Immunotherapy: Dinutuximab Beta Redefines Survival in Relapsed and High-Risk Neuroblastoma

By MedXY 01/20/2026

Recent clinical trials establish dinutuximab beta as a cornerstone of neuroblastoma therapy, demonstrating significant survival benefits when combined with chemotherapy in relapsed cases, while clarifying that adding Interleukin-2 to standard consolidation increases toxicity without improving outcomes.

news Oncology Pediatrics

Denosumab Shows Insufficient Activity in Recurrent Osteosarcoma: Results from a Children’s Oncology Group Phase 2 Trial

By MedXY 01/11/2026

A Phase 2 trial by the Children's Oncology Group found that denosumab, despite its success in other bone-related conditions, failed to meet efficacy benchmarks for recurrent or refractory osteosarcoma, showing no objective responses in patients with measurable disease.

news Oncology Pediatrics

Chromosome 1q Gain, Not Lung Nodule Burden, Best Predicts Outcomes in Stage IV Favorable‑Histology Wilms Tumor

By MedXY 12/08/2025

In AREN0533, number and size of pulmonary metastases had limited prognostic value after standardized therapy; gain of chromosome 1q emerged as a stronger, independent predictor of event‑free and overall survival in children with favorable‑histology Wilms tumor and lung‑only metastases.

Hematology-Oncology Pediatrics Radiology Specialties

Evaluating Radiation Risks from Medical Imaging in Pediatrics: Implications for Hematologic Cancer

By MedXY 09/27/2025

A large cohort study links radiation exposure from pediatric medical imaging to a modest but significant increase in hematologic cancer risk, underlining the need for judicious imaging use in children and adolescents.

Hematology-Oncology Specialties

Tandem CD19/CD22 CAR T-Cell Therapy: A Promising Advance for High-Risk Pediatric and AYA r/r B-ALL

By MedXY 08/29/2025

Tandem CD19/CD22 CAR T-cell therapy shows encouraging safety and efficacy in heavily pretreated children and young adults with relapsed/refractory B-ALL, particularly when combined with consolidative hematopoietic stem cell transplantation.